Brelovitug
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg) . Brelovitug has significant antiviral activity, and neutralizes and removes HBV and HDV as well as depleting HBsAg-containing subviral particles. Brelovitug can be used for HDV and HBV infections, chronic hepatitis delta (CHD) and chronic hepatitis B (CHB) research[1][2].
Product Specifications
CAS Number
3033337-14-0
Product Name Alternative
BJT-778
UNSPSC
12352100
Target
HBV
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection; Inflammation/Immunology
References & Citations
[1]Lampertico P, et al. Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies. Gut. 2025 Apr 7;74 (5) :853-862. |[2]Ramos H J, et al. Characterization of BJT-778, an anti-HBsAg neutralizing monoclonal antibody for treatment of hepatitis B virus and hepatitis D virus infections[C]//EASL Congress. 2024: 5-8.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC741081-100 1x 100 µL
CD45RO (190-2F2.5), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680178-500 1x 500 µL
CD50 (ICAM-3) (186-2G9), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC882085-100 1x 100 µL
TLE1 (Synovial Sarcoma Marker) (TLE1/2085), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880678-500 1x 500 µL
Involucrin (SY5), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details